Inhibitors for targeting flaviviruses
| DWPI Title: Identifying candidate therapeutic for disease caused by viral envelope protein used for treating viral infection arises from flavivirus including mosquito-borne virus, involves contacting test envelope protein with compound, and determining activity of compound with test protein |
| Abstract: The present invention relates to methods for identifying candidate therapeutics for a disease caused by a viral envelope protein. In particular, the method can include contacting a test envelope protein with the candidate and determining its activity. |
| Use: The method is useful for identifying a candidate therapeutic for a disease caused by a viral envelope protein for treating viral infection arises from a flavivirus including a mosquito-borne virus, an Alkhumra hemorrhagic fever virus, Bussuquara virus, Chaoyang virus, Dengue virus, Donggang virus, Ilheus virus, Japanese encephalitis virus, Kedougou virus, Kokobera virus, Kunjin virus, Kyasanur Forest disease virus, Langat virus, Layer flavivirus, Louping ill virus, Murray Valley encephalitis virus, Omsk hemorrhagic fever virus, Powassan virus, Rocio virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Usutu virus, West Nile virus, and Zika virus (all claimed).Test details are described but no results given. |
| Advantage: The method restors reactivity of unprotected reactive group. |
| Novelty: Method for identifying a candidate therapeutic for a disease caused by a viral envelope protein, involves contacting a test envelope protein with a compound, and determining an activity of the compound with the test protein, where the test protein comprises a first sequence having at least 80% sequence identity to any one of 3 (31) nucleotide sequence (SEQ ID No. 35-104) fully defined in the specification, or SEQ ID NOs:105, 106, 179, 181, 182, 185, 187, or 188. The test protein comprises a second sequence having at least 80% sequence identity to any one of SEQ ID NOs: 107-176, or SEQ ID NOs: 177, 178, 180, 183, 184, 186, or 189-191. The second sequence comprises a lysine at position 9 and/or position 10. The activity indicates greater inhibition of viral entry, as compared to a control |
| Filed: 11/14/2019 |
| Application Number: US16684445A |
| Tech ID: SD 14125.1 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |